Related references
Note: Only part of the references are listed.Cutting Edge: Active TGF-β1 Released from GARP/TGF-β1 Complexes on the Surface of Stimulated Human B Lymphocytes Increases Class-Switch Recombination and Production of IgA
Olivier Dedobbeleer et al.
JOURNAL OF IMMUNOLOGY (2017)
Tumour-associated macrophages as treatment targets in oncology
Alberto Mantovani et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Maturation-dependent expression of AIM2 in human B-cells
Alexandra Svensson et al.
PLOS ONE (2017)
CD40 ligand-expressing recombinant vaccinia virus promotes the generation of CD8+ central memory Tcells
Emanuele Trella et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2016)
Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: a Novel Method to Handle the Interval Censoring Caused by Measurement of Smaller Tumors
Philippe B. Pierrillas et al.
AAPS JOURNAL (2016)
Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients
Angelica Loskog et al.
BRITISH JOURNAL OF CANCER (2016)
A Breakthrough: Macrophage-Directed Cancer Immunotherapy
Charles D. Mills et al.
CANCER RESEARCH (2016)
T-helper signals restore B-cell receptor signaling in autoreactive anergic B cells by upregulating CD45 phosphatase activity
Peter Szodoray et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice
Virginia A. Carroll et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
NORE1A induction by membrane-bound CD40L (mCD40L) contributes to CD40L-induced cell death and G1 growth arrest in p21-mediated mechanism
T. Elmetwali et al.
CELL DEATH & DISEASE (2016)
Macrophages and Therapeutic Resistance in Cancer
Brian Ruffell et al.
CANCER CELL (2015)
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study
Philippe A. Cassier et al.
LANCET ONCOLOGY (2015)
STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis
Chanyu Yue et al.
CANCER IMMUNOLOGY RESEARCH (2015)
VEGFA gene locus analysis across 80 human tumour types reveals gene amplification in several neoplastic entities
Mariacarla Andreozzi et al.
ANGIOGENESIS (2014)
GM-CSF Production by Tumor Cells Is Associated with Improved Survival in Colorectal Cancer
Christian A. Nebiker et al.
CLINICAL CANCER RESEARCH (2014)
CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging
S. Parviainen et al.
GENE THERAPY (2014)
Tumor-Associated Macrophages: From Mechanisms to Therapy
Roy Noy et al.
IMMUNITY (2014)
Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
James L. Gulley et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer
Lee P. Richman et al.
CANCER IMMUNOLOGY RESEARCH (2014)
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
Shahneen K. Sandhu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
CD40 immunotherapy for pancreatic cancer
Robert H. Vonderheide et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2013)
Agonistic CD40 Antibodies and Cancer Therapy
Robert H. Vonderheide et al.
CLINICAL CANCER RESEARCH (2013)
Targeting tumor-infiltrating macrophages to combat cancer
Roheena Z. Panni et al.
IMMUNOTHERAPY (2013)
Tumor-associated macrophages: functional diversity, clinical significance, and open questions
Subhra K. Biswas et al.
SEMINARS IN IMMUNOPATHOLOGY (2013)
Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma
Gregory L. Beatty
ONCOIMMUNOLOGY (2013)
The Immune Microenvironment of Human Tumors: General Significance and Clinical Impact
Wolf-Herman Fridman et al.
CANCER MICROENVIRONMENT (2013)
Poxviral vectors for cancer immunotherapy
Joseph W. Kim et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
AdCD40L-Crossing the Valley of Death?
Gustav Ullenhag et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2012)
Macrophage plasticity and polarization: in vivo veritas
Antonio Sica et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic
Basav N. Hangalapura et al.
JOURNAL OF GENE MEDICINE (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies
Elke Schultz-Thater et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Gregory L. Beatty et al.
SCIENCE (2011)
Macrophage Diversity Enhances Tumor Progression and Metastasis
Bin-Zhi Qian et al.
CELL (2010)
AdCD40L Immunogene Therapy for Bladder Carcinoma-The First Phase I/IIa Trial
Per-Uno Malmstrom et al.
CLINICAL CANCER RESEARCH (2010)
Macrophages, innate immunity and cancer: balance, tolerance, and diversity
Alberto Mantovani et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
CD40 Ligand-Induced Carcinoma Cell Death: A Balance between Activation of TNFR-Associated Factor (TRAF) 3-Dependent Death Signals and Suppression of TRAF6-Dependent Survival Signals
Taha Elmetwali et al.
JOURNAL OF IMMUNOLOGY (2010)
Intranodal Immunization With a Vaccinia Virus Encoding Multiple Antigenic Epitopes and Costimulatory Molecules in Metastatic Melanoma
Michel Adamina et al.
MOLECULAR THERAPY (2010)
Molecular mechanism and function of CD40/CD40L engagement in the immune system
Raul Elgueta et al.
IMMUNOLOGICAL REVIEWS (2009)
Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligand
Agnes Wyzgol et al.
JOURNAL OF IMMUNOLOGY (2009)
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
David H. Kirn et al.
NATURE REVIEWS CANCER (2009)
Prospect of targeting the CD40 pathway for cancer therapy
Robert H. Vonderheide
CLINICAL CANCER RESEARCH (2007)
A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-κB and enhanced IRF-3/STAT1 activation)
SK Biswas et al.
BLOOD (2006)
Signals required for programming effector and memory development by CD8(+) T cells
Matthew F. Mescher et al.
IMMUNOLOGICAL REVIEWS (2006)
CD8(+) T-cell memory in tumor immunology and immunotherapy
Christopher A. Klebanoff et al.
IMMUNOLOGICAL REVIEWS (2006)
Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses
C Feder-Mengus et al.
HUMAN GENE THERAPY (2005)
Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2, macrophages subvert, immunity to (myco)bacteria
FAW Verreck et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients
P Zajac et al.
HUMAN GENE THERAPY (2003)
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes
A Mantovani et al.
TRENDS IN IMMUNOLOGY (2002)
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides
S Zwaveling et al.
JOURNAL OF IMMUNOLOGY (2002)
The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies
L Bingle et al.
JOURNAL OF PATHOLOGY (2002)
Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen
A Schütz et al.
CANCER GENE THERAPY (2001)
Share Paper
